Imugene snags Chinese patent for sublingual bone-loss drug; Florida researchers develop DNA 'nanotrain' for targeted delivery;

> Australian company Imugene won a Chinese patent for its delivery tech Linguet, a bone-loss drug for osteoporosis with a platform that allows absorption in the mouth. Release

> Researchers at the University of Florida developed a "DNA nanotrain" to carry cancer drugs and bioimaging agents to tumor cells in a cost-effective way. Story

> Emergent Technologies and Caisson Biotech, the team that created the HEPtune drug delivery system that enhances drugs by increasing their half-life, joined with Seton Healthcare Family to expand the system's use. Release

> Sensile Medical partnered with scPharmaceuticals to develop and manufacture an automated patch pump that delivers furosemide under the skin. Release

> Andain has developed an inhaled nanoparticle solution for the treatment of chronic obstructive pulmonary disease. The lipid-based nanoparticles absorb in the body with no adverse effects, the company says. Release

Suggested Articles

Kala Pharma's Eysuvis on Tuesday became the first and only corticosteroid approved to treat short-term signs and symptoms of dry eye disease.

Xeris scored an FDA fast track designation for its diazepam formulation, delivered via autoinjector, to treat acute repetitive seizures.

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.